Agoracom: Small Cap Investment - Resverlogix Corp. - Re: RVX ANNOUNCES DOSING OF FIRST TWO PATIENTS IN EXPANDED RENAL AND ORPHAN PROGRAMS

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Back To Forum List View

RVX ANNOUNCES DOSING OF FIRST TWO PATIENTS IN EXPANDED RENAL AND ORPHAN PROGRAMS

BearDownAZ

Jul 21, 2016 02:38PM

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: RVX ANNOUNCES DOSING OF FIRST TWO PATIENTS IN EXPANDED RENAL AND ORPHAN PROGRAMS

in response to

RVX ANNOUNCES DOSING OF FIRST TWO PATIENTS IN EXPANDED RENAL AND ORPHAN PROGRAMS

BearDownAZ

posted on Jul 21, 2016 02:42PM

Info on the New Zealand Renal Phase 1 Trial with RVX-208. The Phase 1 New Zealand Renal Trial with RVX-208 (aka apabetalone, RVX000222) is listed on the Australian New Zealand Clinical Trial Registry. If this link doesn't work, search the registry for "Resverlogix" and you'll find it.